216 related articles for article (PubMed ID: 21187272)
1. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.
Bee LA; Bannister K; Rahman W; Dickenson AH
Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272
[TBL] [Abstract][Full Text] [Related]
2. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
3. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
Gonçalves L; Friend LV; Dickenson AH
Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
5. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.
Meske DS; Xie JY; Oyarzo J; Badghisi H; Ossipov MH; Porreca F
Neurosci Lett; 2014 Mar; 562():91-6. PubMed ID: 23969300
[TBL] [Abstract][Full Text] [Related]
6. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
Largent-Milnes TM; Guo W; Wang HY; Burns LH; Vanderah TW
J Pain; 2008 Aug; 9(8):700-13. PubMed ID: 18468954
[TBL] [Abstract][Full Text] [Related]
7. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
[TBL] [Abstract][Full Text] [Related]
8. Effect of tapentadol on neurons in the locus coeruleus.
Torres-Sanchez S; Alba-Delgado C; Llorca-Torralba M; Mico JA; Berrocoso E
Neuropharmacology; 2013 Sep; 72():250-8. PubMed ID: 23664814
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
[TBL] [Abstract][Full Text] [Related]
10. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
[TBL] [Abstract][Full Text] [Related]
11. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain.
Mao XF; Ahsan MZ; Apryani E; Tang XQ; Zhao MJ; Li XY; Wang YX
Eur J Pharmacol; 2020 Jun; 876():173062. PubMed ID: 32173379
[TBL] [Abstract][Full Text] [Related]
12. Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach.
Falk S; Patel R; Heegaard A; Mercadante S; Dickenson AH
Eur J Pain; 2015 Feb; 19(2):152-8. PubMed ID: 24917026
[TBL] [Abstract][Full Text] [Related]
13. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
14. Depression of C fibre-evoked spinal field potentials by the spinal delta opioid receptor is enhanced in the spinal nerve ligation model of neuropathic pain: involvement of the mu-subtype.
Buesa I; Urrutia A; Aira Z; Salgueiro M; Bilbao J; Mozas M; Aguilera L; Zimmermann M; Azkue JJ
Neuropharmacology; 2008 Dec; 55(8):1376-82. PubMed ID: 18775732
[TBL] [Abstract][Full Text] [Related]
15. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
16. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
[TBL] [Abstract][Full Text] [Related]
17. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
Kögel B; De Vry J; Tzschentke TM; Christoph T
Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
[TBL] [Abstract][Full Text] [Related]
18. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
Christoph T; De Vry J; Tzschentke TM
Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
[TBL] [Abstract][Full Text] [Related]
19. Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations.
Bannister K; Patel R; Goncalves L; Townson L; Dickenson AH
Pain; 2015 Sep; 156(9):1803-1811. PubMed ID: 26010460
[TBL] [Abstract][Full Text] [Related]
20. Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain.
Torres-Sanchez S; Borges GDS; Mico JA; Berrocoso E
Neuropharmacology; 2018 Jun; 135():202-210. PubMed ID: 29551688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
